New drug tested for rare immune disorder in china
NCT ID NCT05744063
Summary
This study tested the safety and effectiveness of the drug emapalumab in Chinese patients with primary hemophagocytic lymphohistiocytosis (pHLH), a rare and serious immune system disorder. The 13 participants had already tried other standard treatments without sufficient success. Researchers monitored how patients responded to emapalumab and whether it could help control their disease enough to prepare them for a stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Swedish Orphan Biovitrum Research site
Shanghai, Fudan, China
-
Swedish Orphan Biovitrum Research site
Beijing, Xicheng, China
-
Swedish Orphan Biovitrum Research site
Beijing, China
-
Swedish Orphan Biovitrum Research site
Chongqing, China
-
Swedish Orphan Biovitrum Research site
Guangzhou, China
-
Swedish Orphan Biovitrum Research site
Nanjing, China
-
Swedish Orphan Biovitrum Research site
Zhengzhou, China
Conditions
Explore the condition pages connected to this study.